March 13, 2025 Ryvu Therapeutics S.A. Annual Report 2024
Read More
February 25, 2025 Disclosure of delayed inside information regarding the decision to commence the collective redundancy process in the Company and the commencement of the consultation procedure with representatives of the Company’s employees
Read More
February 25, 2025 Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Read More
February 17, 2025 Conclusion of funding agreement with the Małopolska Centre for Entrepreneurship
Read More
February 7, 2025 Recommendation of Ryvu’s project for funding by the Medical Research Agency
Read More
February 7, 2025 Recommendation of Ryvu’s project for funding by the Medical Research Agency
Read More
January 30, 2025 Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE
Read More
